

McMMAF

Catalog No: tcsc5344



Available Sizes

Size: 1mg

Size: 5mg

Size: 10mg



Specifications

CAS No:

863971-19-1

Formula:

$C_{49}H_{76}N_6O_{11}$

Pathway:

Cell Cycle/DNA Damage;Cytoskeleton;Antibody-drug Conjugate/ADC Related

Target:

Microtubule/Tubulin;Microtubule/Tubulin;Drug-Linker Conjugates for ADC

Purity / Grade:

>98%

Solubility:

10 mM in DMSO

Alternative Names:

Maleimidocaproyl monomethylauristatin F

Observed Molecular Weight:


925.16

Product Description

Mc-MMAF is a protective group-conjugated MMAF. MMAF is a more potent drug than Monomethyl auristatin E (MMAE), but is charged and relatively membrane-impermeable, is a potent tubulin inhibitor, is a toxin payload in antibody drug conjugate.

Target:

MMAF is a new auristatin derivative with a charged C-terminal phenylalanine that attenuates its cytotoxic activity compared to its uncharged counterpart, Monomethyl auristatin E (MMAE). Because of MMAF is highly toxic, it cannot be used as a drug itself. MMAF induces potent antitumor effects when conjugated via protease cleavable linkers to a monoclonal antibody targeting internalizing, tumor-specific cell surface antigens. The linker to the monoclonal antibody is stable in extracellular fluid, but is cleaved by cathepsin once the conjugate has entered a tumor cell, thus activating the anti-mitotic mechanism.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!